# A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

> **NCT05732454** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 58 (actual)

## Conditions studied

- Atopic Dermatitis
- Atopic Dermatitis, Unspecified
- Eczema
- Eczema, Atopic

## Interventions

- **DRUG:** etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05732454
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-18
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Per the results of the planned interim analysis, the study met futility criteria for efficacy so the trial was terminated. This decision was made for efficacy reasons only and is not due to any safety concerns.
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732454, "A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05732454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*